CA2347940A1 - Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation - Google Patents

Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation Download PDF

Info

Publication number
CA2347940A1
CA2347940A1 CA002347940A CA2347940A CA2347940A1 CA 2347940 A1 CA2347940 A1 CA 2347940A1 CA 002347940 A CA002347940 A CA 002347940A CA 2347940 A CA2347940 A CA 2347940A CA 2347940 A1 CA2347940 A1 CA 2347940A1
Authority
CA
Canada
Prior art keywords
core
oligosaccharide
cell
compound
selectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002347940A
Other languages
English (en)
Inventor
Jamey D. Marth
Lesley G. Ellies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2347940A1 publication Critical patent/CA2347940A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés et le traitement d'inflammation. Ces composés modulent la liaison induite par le 2 oligosaccharide du noyau des cellules inflammatoires, tels que les neutrophiles, avec les cellules endothéliales et autres cellules myéloïdes. Les procédés de cette invention bloquent l'inflammation de façon significative sans affecter le trafic des lymphocytes. Dans certains modes de réalisation, les composés inhibent l'activité d'une 2 GlcNAc transférase intervenant dans la synthèse des 2 oligosaccharides des noyaux.
CA002347940A 1998-11-21 1999-11-20 Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation Abandoned CA2347940A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10941698P 1998-11-21 1998-11-21
US11367998P 1998-12-21 1998-12-21
US60/113,679 1998-12-21
US60/109,416 1998-12-21
PCT/US1999/027465 WO2000031109A1 (fr) 1998-11-21 1999-11-20 Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation

Publications (1)

Publication Number Publication Date
CA2347940A1 true CA2347940A1 (fr) 2000-06-02

Family

ID=26806952

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002347940A Abandoned CA2347940A1 (fr) 1998-11-21 1999-11-20 Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation

Country Status (5)

Country Link
EP (1) EP1131334A4 (fr)
JP (1) JP2002530425A (fr)
AU (1) AU1629700A (fr)
CA (1) CA2347940A1 (fr)
WO (1) WO2000031109A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4599027B2 (ja) * 2002-10-30 2010-12-15 東洋水産株式会社 Ｌ−セレクチン結合阻害剤
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5461143A (en) * 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5360733A (en) * 1992-10-01 1994-11-01 La Jolla Cancer Research Foundation Human β1-6 n-acetylglucosaminyl transferase
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
AU723262B2 (en) * 1995-08-03 2000-08-24 Board Of Regents Of The University Of Oklahoma, The Peptide and O-glycan inhibitors of selectin mediated inflammation
CA2186987A1 (fr) * 1996-10-02 1998-04-02 George L. King Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete

Also Published As

Publication number Publication date
AU1629700A (en) 2000-06-13
EP1131334A4 (fr) 2003-05-21
WO2000031109A1 (fr) 2000-06-02
EP1131334A1 (fr) 2001-09-12
JP2002530425A (ja) 2002-09-17

Similar Documents

Publication Publication Date Title
Ellies et al. Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation
Wang et al. Endothelial heparan sulfate deficiency impairs L-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses
Malý et al. The α (1, 3) fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis
Smith et al. Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus
Wang et al. Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent functions in mammalian physiology and insights into disease pathogenesis
Asano et al. Growth retardation and early death of β-1, 4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells
Tenno et al. Initiation of protein O glycosylation by the polypeptide GalNAcT-1 in vascular biology and humoral immunity
US6376475B1 (en) Control of immune responses by modulating activity of glycosyltransferases
Asano et al. Impaired selectin-ligand biosynthesis and reduced inflammatory responses in β-1, 4-galactosyltransferase-I–deficient mice
US20030216295A1 (en) E-selectin-dependent cell adhesion antagonists
Hellbusch et al. Golgi GDP-fucose transporter-deficient mice mimic congenital disorder of glycosylation IIc/leukocyte adhesion deficiency II
US20040038923A1 (en) Blocking inflammation by inhibiting sialylation
CA2347940A1 (fr) Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation
US7674577B2 (en) Diagnosis of human glycosylation disorders
Bessler et al. Paroxysmal nocturnal hemoglobinuria: insights from recent advances in molecular biology
US7256171B1 (en) Use of core 2 G1cNAc transferase inhibitors in treating inflammation
US7192914B1 (en) Prevention of atherosclerosis and undesired blood clotting by reducing von Willebrand factor
US20080031821A1 (en) USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION
US20080227689A1 (en) Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1
US7273711B1 (en) Diagnosis of human glycosylation disorders
WO2004006939A1 (fr) Blocage d'une inflammation par inhibition de l'activite de st3-gal-vi
Fukumoto et al. Genetic remodeling of gangliosides resulted in the enhanced reactions to the foreign substances in skin
US8034556B2 (en) Regulation of glucose and insulin levels by GnT-4 glycosyltransferase activity
YOSHIMURA et al. Bisecting GlcNAc structure is implicated in suppression of stroma-dependent haemopoiesis in transgenic mice expressing N-acetylglucosaminyltransferase III
WO2001022921A2 (fr) Prevention de l'atherosclerose et d'une coagulation indesirable du sang par une reduction du facteur von willebrand

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead